Joel Pires
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Joel Pires has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
Diogo Tomé
Center for Neuroscience and Cell Biology, University of Coimbra
2 shared publications- Graça Baltazar
RISE-Health, Department of Medical Sciences, Faculty of Health Sciences, University of Beira Interior, Av. Infante D. Henrique, 6200-506 Covilhã, Portugal
2 shared publications - Liliana Bernardino
Department of Medical Sciences, Faculty of Health Sciences, RISE-Health, UBI, University of Beira Interior, Covilhã, Portugal
2 shared publications - Ramiro D. Almeida
Institute of Biomedicine (iBiMED), Department of Medical Science, University of Aveiro, 3810-193 Aveiro, Portugal
2 shared publications - Sandra Moreira Rocha
Health Sciences Research Centre, Faculty of Health Sciences, University of Beira Interior, Covilhã, Portugal
2 shared publications A. Carvalho
1 shared publication
Latest Publications
- Open Access
- 10 June 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (24)
The tyrosine phosphatase STEP is a developmental suppressor of synaptogenesis
Striatal-Enriched Protein Tyrosine Phosphatase (STEP) constrains synaptic potentiation by dephosphorylating postsynaptic substrates, but its presynaptic role has remained unclear. Here, we identify a previously unrecognized function of STEP in regulating axonal differentiation and synapse assembly. Genetic and pharmacological manipulation of STEP in vivo and in vitro show that STEP limits presynaptic maturation by restricting synaptic vesicle protein clustering along developing hippocampal axons. Using a reconstituted circuit-on-a-chip we show that loss of presynaptic STEP is sufficient to significantly increase the number of axodendritic synapses. Functional imaging further revealed that the increased synaptic puncta observed in STEP KO neurons actively undergo depolarization-evoked vesicle exocytosis, representing bona fide functional synapses. Multielectrode array recordings reveal that STEP deletion increases neuronal excitability, and network synchrony, hallmarks of enhanced presynaptic efficacy. Mechanistically, these effects reflect sustained phosphorylation of STEP promoting presynaptic assembly and release competence. Importantly, inhibiting STEP also rescues presynaptic differentiation defects in Fmr1 KO neurons, implicating aberrant STEP signaling in Fragile X–associated synaptic pathology. Thus, STEP serves as a phosphatase gatekeeper that restrains presynaptic differentiation and neurotransmission, and its inhibition may offer a therapeutic strategy to correct synaptic deficits in Fragile X Syndrome.
- 10 June 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (24)
Open AccessThe tyrosine phosphatase STEP is a developmental suppressor of synaptogenesis
Striatal-Enriched Protein Tyrosine Phosphatase (STEP) constrains synaptic potentiation by dephosphorylating postsynaptic substrates, but its presynaptic role has remained unclear. Here, we identify a previously unrecognized function of STEP in regulating axonal differentiation and synapse assembly. Genetic and pharmacological manipulation of STEP in vivo and in vitro show that STEP limits presynaptic maturation by restricting synaptic vesicle protein clustering along developing hippocampal axons. Using a reconstituted circuit-on-a-chip we show that loss of presynaptic STEP is sufficient to significantly increase the number of axodendritic synapses. Functional imaging further revealed that the increased synaptic puncta observed in STEP KO neurons actively undergo depolarization-evoked vesicle exocytosis, representing bona fide functional synapses. Multielectrode array recordings reveal that STEP deletion increases neuronal excitability, and network synchrony, hallmarks of enhanced presynaptic efficacy. Mechanistically, these effects reflect sustained phosphorylation of STEP promoting presynaptic assembly and release competence. Importantly, inhibiting STEP also rescues presynaptic differentiation defects in Fmr1 KO neurons, implicating aberrant STEP signaling in Fragile X–associated synaptic pathology. Thus, STEP serves as a phosphatase gatekeeper that restrains presynaptic differentiation and neurotransmission, and its inhibition may offer a therapeutic strategy to correct synaptic deficits in Fragile X Syndrome.
- Open Access
- 24 October 2024
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 16 (44) , 60828-60841
Functionalized Nanodiamonds for Targeted Neuronal Electromagnetic Signal Detection
Intracellular sensing technologies necessitate a delicate balance of spatial resolution, sensitivity, biocompatibility, and stability. While existing methods partially fulfill these criteria, none offer a comprehensive solution. Nanodiamonds (NDs) harboring nitrogen-vacancy (NV) centers have emerged as promising candidates due to their sensing capabilities under biological conditions and their ability to meet all aforementioned requirements. This study focuses on expanding the application of NDs and NV center-based sensing to neuronal contexts by investigating their functionalization and subsequent effects on three distinct cell lines relevant to neurodegenerative disease research. Our study concentrates on positioning fluorescent NDs (FNDs) with NV center point defects onto neuronal cell surfaces. Achieving this through specific antibody attachment enhances the proximity of FND to neurites, facilitating the detection of local action potentials. Targeting voltage-dependent calcium channels (Cav2.2) with biotin-streptavidin-bound antibodies enables the precise positioning of FNDs. The functionalized FNDs (f-FNDs) show increased size and zeta potential, confirming the antibody presence without compromising cell viability. Two-color confocal imaging and co-localization algorithms are employed to further attest to the success of the functionalization. The f-FNDs are applied to cell cultures of three cell lines: SH-SY5Y, differentiated dopaminergic neurons, and hippocampal rat neurons; their biocompatibility and effects on synaptic activity are explored. Moreover, preliminary total internal reflection fluorescence - optically detected magnetic resonance (TIRF-ODMR) experiments across cellular sites demonstrate the magnetic field sensitivity of our sensor network. The successful establishment of this sensor network provides a platform for characterizing neuronal signaling in healthy models and conditions mimicking Parkinson's disease.
- 24 October 2024
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 16 (44) , 60828-60841
Open AccessFunctionalized Nanodiamonds for Targeted Neuronal Electromagnetic Signal Detection
Intracellular sensing technologies necessitate a delicate balance of spatial resolution, sensitivity, biocompatibility, and stability. While existing methods partially fulfill these criteria, none offer a comprehensive solution. Nanodiamonds (NDs) harboring nitrogen-vacancy (NV) centers have emerged as promising candidates due to their sensing capabilities under biological conditions and their ability to meet all aforementioned requirements. This study focuses on expanding the application of NDs and NV center-based sensing to neuronal contexts by investigating their functionalization and subsequent effects on three distinct cell lines relevant to neurodegenerative disease research. Our study concentrates on positioning fluorescent NDs (FNDs) with NV center point defects onto neuronal cell surfaces. Achieving this through specific antibody attachment enhances the proximity of FND to neurites, facilitating the detection of local action potentials. Targeting voltage-dependent calcium channels (Cav2.2) with biotin-streptavidin-bound antibodies enables the precise positioning of FNDs. The functionalized FNDs (f-FNDs) show increased size and zeta potential, confirming the antibody presence without compromising cell viability. Two-color confocal imaging and co-localization algorithms are employed to further attest to the success of the functionalization. The f-FNDs are applied to cell cultures of three cell lines: SH-SY5Y, differentiated dopaminergic neurons, and hippocampal rat neurons; their biocompatibility and effects on synaptic activity are explored. Moreover, preliminary total internal reflection fluorescence - optically detected magnetic resonance (TIRF-ODMR) experiments across cellular sites demonstrate the magnetic field sensitivity of our sensor network. The successful establishment of this sensor network provides a platform for characterizing neuronal signaling in healthy models and conditions mimicking Parkinson's disease.
- Open Access
- 24 November 2021
- Published by MDPI AG in Biomedicines
- Vol. 9 (12) , 1754
Preclinical Assessment of Mesenchymal-Stem-Cell-Based Therapies in Spinocerebellar Ataxia Type 3
The low regeneration potential of the central nervous system (CNS) represents a challenge for the development of new therapeutic strategies for neurodegenerative diseases, including spinocerebellar ataxias. Spinocerebellar ataxia type 3 (SCA3)—or Machado–Joseph disease (MJD)—is the most common dominant ataxia, being mainly characterized by motor deficits; however, SCA3/MJD has a complex and heterogeneous pathophysiology, involving many CNS brain regions, contributing to the lack of effective therapies. Mesenchymal stem cells (MSCs) have been proposed as a potential therapeutic tool for CNS disorders. Beyond their differentiation potential, MSCs secrete a broad range of neuroregulatory factors that can promote relevant neuroprotective and immunomodulatory actions in different pathophysiological contexts. The objective of this work was to study the effects of (1) human MSC transplantation and (2) human MSC secretome (CM) administration on disease progression in vivo, using the CMVMJD135 mouse model of SCA3/MJD. Our results showed that a single CM administration was more beneficial than MSC transplantation—particularly in the cerebellum and basal ganglia—while no motor improvement was observed when these cell-based therapeutic approaches were applied in the spinal cord. However, the effects observed were mild and transient, suggesting that continuous or repeated administration would be needed, which should be further tested.
- 24 November 2021
- Published by MDPI AG in Biomedicines
- Vol. 9 (12) , 1754
Open AccessPreclinical Assessment of Mesenchymal-Stem-Cell-Based Therapies in Spinocerebellar Ataxia Type 3
The low regeneration potential of the central nervous system (CNS) represents a challenge for the development of new therapeutic strategies for neurodegenerative diseases, including spinocerebellar ataxias. Spinocerebellar ataxia type 3 (SCA3)—or Machado–Joseph disease (MJD)—is the most common dominant ataxia, being mainly characterized by motor deficits; however, SCA3/MJD has a complex and heterogeneous pathophysiology, involving many CNS brain regions, contributing to the lack of effective therapies. Mesenchymal stem cells (MSCs) have been proposed as a potential therapeutic tool for CNS disorders. Beyond their differentiation potential, MSCs secrete a broad range of neuroregulatory factors that can promote relevant neuroprotective and immunomodulatory actions in different pathophysiological contexts. The objective of this work was to study the effects of (1) human MSC transplantation and (2) human MSC secretome (CM) administration on disease progression in vivo, using the CMVMJD135 mouse model of SCA3/MJD. Our results showed that a single CM administration was more beneficial than MSC transplantation—particularly in the cerebellum and basal ganglia—while no motor improvement was observed when these cell-based therapeutic approaches were applied in the spinal cord. However, the effects observed were mild and transient, suggesting that continuous or repeated administration would be needed, which should be further tested.
- Open Access
- 20 June 2017
- Published by STEF92 Technology
- Vol. 32
MODELING SOIL EROSION POTENTIAL USING USLE AND GIS TOOLS IN THE WATERSHEDS OF COVILHA REGION (PORTUGAL)
- 20 June 2017
- Published by STEF92 Technology
- Vol. 32
Open AccessMODELING SOIL EROSION POTENTIAL USING USLE AND GIS TOOLS IN THE WATERSHEDS OF COVILHA REGION (PORTUGAL)
- 1 March 2017
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- Vol. 1863 (3) , 764-769
Dual role of histamine on microglia-induced neurodegeneration
- 1 March 2017
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- Vol. 1863 (3) , 764-769
Dual role of histamine on microglia-induced neurodegeneration
- Open Access
- 30 April 2014
- Published by Frontiers Media SA in Frontiers in Cellular Neuroscience
- Vol. 8, 120
Histamine: a new immunomodulatory player in the neuron-glia crosstalk
Histamine is an amine acting as a major peripheral inflammatory mediator. In the brain, histamine was initially viewed as a neurotransmitter, but new evidences support its involvement in the modulation of innate immune responses. Recently, we showed that histamine modulates microglial migration and cytokine release. Its pleiotropic actions, ranging from neurotransmission to inflammation, highlight histamine as a key player in a vast array of brain physiologic activities and also in the pathogenesis of several neurodegenerative diseases. Herein, we emphasize the role of histamine as a modulator of brain immune reactions, either by acting on invading peripheral immune cells and/or on resident microglial cells. We also unveil the putative involvement of histamine in the microglial-neuronal communication. We first show that histamine modulates the release of inflammatory mediators, namely nitric oxide, by microglia cells. Consequently, the microglia secretome released upon histamine stimulation fosters dopaminergic neuronal death. These data may reveal important new pharmacological applications on the use histamine and antihistamines, particularly in the context of Parkinson’s disease.
- 30 April 2014
- Published by Frontiers Media SA in Frontiers in Cellular Neuroscience
- Vol. 8, 120
Open AccessHistamine: a new immunomodulatory player in the neuron-glia crosstalk
Histamine is an amine acting as a major peripheral inflammatory mediator. In the brain, histamine was initially viewed as a neurotransmitter, but new evidences support its involvement in the modulation of innate immune responses. Recently, we showed that histamine modulates microglial migration and cytokine release. Its pleiotropic actions, ranging from neurotransmission to inflammation, highlight histamine as a key player in a vast array of brain physiologic activities and also in the pathogenesis of several neurodegenerative diseases. Herein, we emphasize the role of histamine as a modulator of brain immune reactions, either by acting on invading peripheral immune cells and/or on resident microglial cells. We also unveil the putative involvement of histamine in the microglial-neuronal communication. We first show that histamine modulates the release of inflammatory mediators, namely nitric oxide, by microglia cells. Consequently, the microglia secretome released upon histamine stimulation fosters dopaminergic neuronal death. These data may reveal important new pharmacological applications on the use histamine and antihistamines, particularly in the context of Parkinson’s disease.